To evaluate the administration of single doses of 2-HOBA in humans, with an escalation of
doses that begins with the calculated Maximum Recommended Starting Dose. This evaluation
will assess tolerability to oral administration of 2-HOBA, obtain pharmacokinetic data,
characterize the 2-HOBA metabolic pathways, and determine the relation of dose to prevention
of formation of bi-functional electrophile adducts in blood. Characterization of the
metabolic fate of 2-HOBA will be supported by investigations that evaluate metabolism in
microsomes, cells and other species.
Phase:
Phase 1
Details
Lead Sponsor:
Vanderbilt University
Collaborators:
Metabolic Technologies Inc. National Institute on Aging (NIA)